Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKA

NCT06509958 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

15

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's R\&D Strategy adjusted

Conditions

Postoperative Pain Management in Total Knee Arthroplasty

Interventions

DRUG: HR18034
DRUG: Ropivacaine Hydrochloride Injection

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.